**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript No: 11636**

**Columns: TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (2): Hepatitis C virus

**Lipoproteins and neutralizing activity of antibodies directed against hepatitis C virus or its receptors**

Vercauteren K *et al*. Lipoproteins and HCV entry neutralizing antibodies

Koen Vercauteren, Ahmed Atef Mesalam, Geert Leroux-Roels, Philip Meuleman

**Koen Vercauteren, Ahmed Atef Mesalam, Geert Leroux-Roels and Philip Meuleman,** Center for Vaccinology, Ghent University Hospital, Ghent University, B-9000 Ghent, Belgium

**Author contributions:** Vercauteren K and Mesalam AA wrote the paper; Leroux-Roels g and Meuleman P critically revised it.

**Supported by** Ghent University, Grants No. 01G00507 and No. 01G01712); Research Foundation – Flanders, Projects No. 1500910N, No. G0212.10N and No. G052112N (FWO-Vlaanderen); Belgian Federal Government, No. IUAP P6/36-HEPRO and No. P7/47-HEPRO-2; and European Union (FP6 HEPACIVAC; FP7, HepaMab)

**Correspondence to: Philip Meuleman, Professor,** Center for Vaccinology, Ghent University Hospital, Ghent University, Building A, 1st floor, De Pintelaan 185, B-9000 Gent, Belgium. philip.meuleman@ugent.be

**Telephone:** +32-9-3323658  **Fax:** +32-9-3326311

**Received:** May 28, 2014 **Revised:** July 9, 2014

**Accepted:** September 5, 2014

**Published online:**

**Abstract**

Hepatitis C virus (HCV) infections represent a major global health problem. End-stage liver disease caused by chronic HCV infection is a major indication for liver transplantation. However, after transplantation the engrafted liver inevitably becomes infected by the circulating virus. Direct acting antivirals are not yet approved for use in liver transplant patients, and limited efficacy and severe side effects hamper the use of pegylated interferon combined with ribavirin in a post-transplant setting. Therefore, alternative therapeutic options need to be explored. Viral entry represents an attractive target for such therapeutic intervention. Understanding the mechanisms of viral entry is essential to define the viral and cellular factors involved. The HCV life cycle is dependent of and associated with lipoprotein physiology and the presence of lipoproteins has been correlated with altered antiviral efficacy of entry inhibitors. In this review, we summarise the current knowledge on how lipoprotein physiology influences the HCV life cycle. We focus especially on the influence of lipoproteins on antibodies that target HCV envelope proteins or antibodies that target the cellular receptors of the virus. This information can be particularly relevant for the prevention of HCV re-infection after liver transplantation.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Hepatitis; Lipids; Neutralisation; Antiviral therapy; Animal models

**Core tip:** In this review we discuss the impact of circulating lipoproteins in the blood, which might have an influence on novel anti-hepatitis C virus therapies that target the viral envelope proteins or that target one of the receptors the virus uses to infect the hepatocytes.

Vercauteren K, Mesalam AA, Leroux-Roels G, Meuleman P. Lipoproteins and neutralizing activity of antibodies directed against hepatitis C virus or its receptors. *World J Gastroenterol* 2014; In press

**Introduction**

Approximately 3% of the world’s population is chronically infected with the hepatitis C virus. Depending on the genotype of the infecting virus, 50% to 80% of chronically infected patients clear the virus upon treatment with pegylated interferon and ribavirin[[1](#_ENREF_1)]. Addition of one of the recently approved protease inhibitors: telaprevir, boceprevir or simeprevir; or the nucleotide analogue polymerase inhibitor sofosbuvir, significantly increases the response rate in patients infected with HCV genotype 1[[2-4](#_ENREF_2)]. However, side effects and drug-drug interactions severely complicate the use of first wave protease inhibitors in triple therapy in chronically infected patients in need for liver transplantation[[5](#_ENREF_5),[6](#_ENREF_6)]. Therefore, cocktails of other direct acting antivirals (DAAs) without interferon are needed to treat this expanding patient population. Very recently, sofosbuvir has been approved in combination with ribavirin for the treatment of chronic HCV patients with hepatocellular carcinoma awaiting liver transplantation in order to prevent post-transplant HCV recurrence. No drug interactions with immunosuppressive therapy were observed and post-transplantation sustained virologic response (SVR) was achieved in more than half of the patients[[7](#_ENREF_7)]. Although promising results have been presented of studies investigating the effect of DAA-based regimens in patients suffering from recurrent HCV[[8-10](#_ENREF_8)], today no therapy exists that protects the liver graft from being infected in viremic pre-transplant patients.

The viral entry process offers multiple targets for the development of alternative strategies for the prevention of HCV recurrence[[11](#_ENREF_11)]. The viral envelope glycoproteins, E1 and E2, are major components of the viral particle and play a pivotal role in the entry process. The envelope protein E2, and especially its hypervariable region 1 (HVR1), is the main target for neutralizing antibodies that are generated by the humoral immune response. Presumably, broadly cross-neutralizing monoclonal antibodies (mAbs) directed against HCV E2 could represent a promising tool for effective passive immunotherapy. However, due to the high propensity of the virus to continually mutate, and the high variability of this region in particular, neutralizing anti-HVR1 antibodies have only limited cross-genotype neutralization potency[[12](#_ENREF_12)]. Nevertheless, neutralizing antibodies play a role in viral protection and disease outcome[[13](#_ENREF_13),[14](#_ENREF_14)]. Therefore, the applicability of HCV neutralizing antibodies as a means of preventing HCV re-infection of liver allografts has been explored. Although proof of concept pre-clinical studies showed promising results[[15-18](#_ENREF_15)], no or only transient effects on HCV RNA levels and HCV recurrence after liver transplantation were observed in clinical studies[[19-22](#_ENREF_19)]. This lack of effectiveness could partially be explained by the observation that human serum, and HDL in particular, lower the neutralization efficacy of anti-HCV neutralizing antibodies[[23-25](#_ENREF_23)].

HCV relies on multiple host cell membrane molecules to establish initial cell contact and other more specific interactions to initiate the ensuing entry into the hepatocyte. Glycosaminoglycans and the LDL-receptor have been proposed to as initial attachment factors for HCV to the surface of the hepatocyte[[26](#_ENREF_26),[27](#_ENREF_27)]. For actual endocytosis, the virus first needs to interact with SR-BI and CD81 before being directed to the tight junction proteins claudin-1 (CLDN1) and occludin[[28-31](#_ENREF_28)]. Blockade of one or more of these host cell factors represent an attractive strategy for antiviral intervention.

During the HCV entry process and different other steps in the viral life cycle, lipids and lipoproteins have been reported to intervene. For example, essential roles for HCV entry have been dedicated to lipid receptors, free lipoproteins and apolipoproteins (Apo) associated with the viral particle, whereas lipid droplets and ApoE expression are important during assembly and release of the viral particle respectively. In this review, we focus on the interaction of lipid physiology with HCV virology and to what extent these interactions influence the antiviral efficacy of entry inhibitors, more specifically neutralizing antibodies targeting either the viral envelope or the cellular (co-)receptors used by HCV for its entry.

**Lipids and lipoprotein metabolism**

Blood plasma and interstitial fluid represent an aqueous environment wherein hydrophilic interactions predominate. To transport hydrophobic lipids throughout the body these are incorporated into water-soluble aggregates of protein and lipid, known as lipoproteins. Lipoproteins are defined by their apolipoprotein, cholesterol, triglyceride and phospholipid content and subdivided by their buoyant densities into high, low, intermediate and very low density lipoproteins (HDL, LDL, IDL and VLDL respectively) and chylomicrons[[32](#_ENREF_32)]. A schematic representation of lipoprotein metabolism can be found in Figure 1.

In the enterocyte, absorbed dietary lipids are re-esterified to triglycerides (TG), cholesteryl esters and phospholipids that, together with fat-soluble vitamins, are assembled and secreted into the bloodstream as TG- and ApoB48-rich chylomicrons. In contrast, endogenously synthesized lipids are secreted by the liver in **VLDL** particles containing ApoB100. Both these ApoB-containing lipoproteins are involved in the lipid delivery pathway and therefore circulate in the blood in order to distribute lipids to peripheral and specific target tissues. This process is controlled by the apolipoproteins present in these particles that act as receptor ligands or enzyme cofactors. ApoCII for example acts as a cofactor for lipoprotein lipases (LPL), which catalyzes the hydrolysis of TG into 2-monoacylglycerol and free or non-esterified fatty acids for tissue utilization as an energy source, for energy storage and thermoregulation in specialized tissues such as muscles, white and brown adipose tissues respectively. The physiological site of action of the lipase is located at the luminal surface of the capillary endothelial cells, because TG-rich lipoprotein particles are too large to cross the capillary endothelium in most tissues. The enzyme is attached to the endothelium *via* highly charged, membrane-bound chains of heparan sulphate-proteoglycans (HSPG).ApoB-containing lipoproteins acquire ApoCII and ApoE in circulation, immediately after secretion or due to protein exchange with HDL. Chylomicron TG can then be hydrolyzed into free fatty acids by LPL, leading to the formation of smaller chylomicron remnants, which are taken up by the liver via ApoE interaction with the LDL-R or the low density lipoprotein receptor-related protein 1 (LRP1). In addition, LPL converts VLDL into ApoE- and cholesterol-rich **IDL** that can also be removed by these receptors. Assisted by hepatic lipase (HL), LPL can further metabolise IDL to LDL, upon which it loses most of its ApoE and can be recognized and internalized by the hepatic LDL-R via its ApoB moiety. The lipid-proteoglycan bridging capacity of these lipases facilitates clearance of lipolytic remnant particles by presentation to hepatic surface proteoglycans before receptor-mediated endocytosis. Although mainly recycled to the liver, LDL can also be taken up by peripheral cells by the LDL-R. Importantly, excess LDL and chylomicron remnants can invade the arterial wall, become oxidized and be taken up by the scavenger receptor on arterial wall macrophages that are hence transformed into foam cells, a process leading to atherosclerosis[[33](#_ENREF_33),[34](#_ENREF_34)].

Besides TG, also cholesterol is transported through the bloodstream via lipoprotein particles. Cholesterol is an essential component of the plasma membrane by maintaining the barrier function between intra- and extracellular environment, modulating its fluidity, and creating “rafts” that concentrate signalling molecules. Cholesterol is transported back to the liver in a process called reverse cholesterol transport that implicates HDL. Nascent HDL is generated by the transfer of phospholipids and cholesterol from peripheral tissues, intestine and liver onto ApoA-1. This process is catalyzed by the ATP-binding cassette A1 (ABCA1) transporter. The cholesterol contained in this nascent HDL is then esterified by lysolecithin cholesterol acyltransferase (LCAT) thereby forming more spherical mature HDL. Additional cholesterol can be loaded onto mature HDL by another ABC transporter, ABCG1. HDL can further capture free cholesterol from membrane pools via interactions with SR-BI, lipid rafts and caveolae. These processes are important in preventing atherosclerotic vessel disease by allowing macrophages to efflux artery wall cholesterol. During their passage through the circulation the ApoE content of HDL increases due to protein exchange with VLDL. In addition, the cholesteryl ester transfer protein (CETP) can transfer cholesteryl ester from HDL to chylomicrons, VLDL and their remnants in exchange for TG. HDL-cholesteryl-esters can be utilized by the liver through the SR-BI receptor. After hydrolysis, free cholesterol can be metabolized to bile acids that are excreted into the digestive tract via biliary secretion. Extrahepatically, SR-BI supports HDL-cholesteryl-esters consumption as a precursor for the manufacture of all steroid hormones[[35](#_ENREF_35),[36](#_ENREF_36)].

**Interplay between patient lipid metabolism, chronic HCV and anti-HCV therapy efficacy**

Chronic HCV infection has been linked to various lipid metabolism disorders. HCV perturbs lipid homeostasis while supporting its own survival but thereby causing liver disease. These HCV-induced lipid homeostasis alterations affect serum lipid profiles that lead to hepatic steatosis, the accumulation of hepatocellular lipid droplets[[37](#_ENREF_37)]. Especially genotype 3 HCV infections are associated with reduced levels of total and LDL cholesterol and with the development of hepatic steatosis[[38](#_ENREF_38)]. In these patients, steatosis and hypocholesterolemia are associated with high viral load[[39](#_ENREF_39)].

It has been observed that HCV infection in humanized mice mediates changes in the hepatic expression of genes that regulate lipid metabolism[[40](#_ENREF_40)]. Also during the early stages of HCV infection in chimpanzees that permanently or transiently cleared the virus upon IFN-γ induction, host genes involved in lipid metabolism were shown to be differentially regulated[[41](#_ENREF_41)]. These observations suggest that lipid metabolism is essential for the HCV life cycle or viral clearance[[40](#_ENREF_40)] and that changes in lipid metabolism can influence the efficacy of anti-HCV treatment. Indeed, pre-treatment serum LDL and cholesterol levels in HCV infected patients were found to directly correlate with response to interferon-based therapy[[42](#_ENREF_42)], while liver steatosis was associated with a lower sustained response rate to interferon-based therapy[[39](#_ENREF_39)]. Furthermore, cholesterol-lowering statins possess anti-HCV capacities[[43](#_ENREF_43),[44](#_ENREF_44)]. However it should be mentioned that their anti-HCV property is not considered to depend on their inhibitory effects on cholesterol biosynthesis, but rather on their capacity to inhibit geranylgeranyl pyrophosphate synthesis, which is important for HCV RNA replication. Although clinical proof of anti-HCV activity of statin monotherapy is lacking or contradictory[[45-48](#_ENREF_45)], its combination with interferon-based therapy may improve virologic response rates[[49-52](#_ENREF_49)]. Another inhibitor of cholesterol synthesis, bezafibrate, only slightly reduced HCV viremia in chronic hepatitis C patients with concomitant hyperlipidaemia[[53](#_ENREF_53)]. Finally, HCV viremia has been shown to inversely correlate with serum triglyceride levels[[54](#_ENREF_54)]. In fact, high triglyceridemia during acute HCV infection may facilitate viral clearance since triglyceridemia was increased in patients that cleared HCV infection[[55](#_ENREF_55)]. Chronic HCV infection is associated with the development of insulin resistance which further promotes the progression of steatosis and fibrosis[[56](#_ENREF_56)]. Since insulin resistance induces interferon resistance, the management of insulin resistance by means of insulin sensitizers such as metformin[[57](#_ENREF_57)] or pioglitazone[[58](#_ENREF_58)] has been proposed to improve interferon-based HCV treatment outcomes, however insulin therapy reduced SVR[[52](#_ENREF_52)].

**viral life cycle is tightly associated with hepatic lipid metabolism pathways**

HCV circulates in the bloodstream as a very heterogeneous population, not only genetically (quasispecies) but also physicochemically. The latter is the result of the association of viral particles with immunoglobulins and lipoproteins. HCV particles vary in density between 1.03 and 1.34 g/ml and the very low-density population appears to be particularly infectious[[59](#_ENREF_59)]. This population is known as lipoviroparticles, *i.e.* lipoprotein-like structures composed of triglyceride-rich lipoproteins containing at least ApoB and E, viral RNA and HCV core protein[[60-62](#_ENREF_60)].

***Effects on HCV entry***

**HCV hepatocyte entry involves lipid receptors:** The scavenger receptor class B type I (SR-BI) is a highly glycosylated 509 amino acid long glycoprotein with a large extracellular domain anchored to the plasma membrane at both the amino- and carboxy-termini. It is concentrated in microdomains that correspond to cholesterol and sphingolipid-enriched plasma membrane microdomains (lipid rafts) called caveolae[[63](#_ENREF_63)]. SR-BI is the principal HDL receptor but it also binds VLDL, LDL and oxidized lipoproteins. SR-BI predominantly mediates selective uptake of HDL-cholesteryl esters (CE) in a two-step process that first involves HDL binding with subsequent incorporation of CE to the plasma membrane pool, followed by hydrolysis to free cholesterol by a neutral CE hydrolase and storage in an intracellular cholesterol pool. This process occurs without catabolism of the HDL particle. In addition, an alternative lipid exchange pathway exists that is thought to gain importance in case of disturbed lipid metabolism and which comprises concomitant endocytosis of SR-BI and whole HDL particles followed by particle re-secretion. HDL re-secretion could be linked to cholesterol efflux, since re-secreted HDL particles are enriched in cellular cholesterol. SR-BI is also involved in bidirectional free cholesterol flux. As mentioned before, it is expressed predominantly in the liver and steroidogenic tissues. In hepatocytes, SR-BI transports cholesteryl esters for membrane function and synthesis of bile acids, thereby participating in reverse cholesterol transport and cholesterol homeostasis. In steroidogenic tissues, such as the adrenal cortex, it delivers cholesteryl esters for the synthesis of glucocorticoids[[63-65](#_ENREF_63)].

Attachment is through ApoE.SR-BI was initially discovered as an HCV (co-)receptor based on its ability to interact with soluble E2 (sE2). Deletion of HVR1 impaired the binding of sE2 to SR-BI suggesting that this region is particularly involved in this interaction. However, more recent data of Thi *et al*[[29](#_ENREF_29)] revealed that the HCV-associated lipoproteins are even more important, for the interaction of the virus with SR-BI. Indeed, intermediate density HCV particles (1.10 to 1.16 g/ml) bound efficiently to human SR-BI expressed on BRL3A cells that are devoid of endogenous SR-BI. Surprisingly, a mutation in HVR1 (L339R) that abrogates sE2 binding to SR-BI, did not alter the ability of cell culture-derived HCV (HCVcc) to bind human SR-BI. In addition, BRL3A cells expressing mouse SR-BI, which is unable to bind sE2, also supported HCVcc binding. Furthermore, despite the observation that Blocker of Lipid Transport-4 (BLT-4) and anti-E2 antibodies both block sE2-SR-BI binding, they did not abrogate HCV-SR-BI binding. In contrast, HCVcc did not attach to a mouse SR-BI variant that is unable to bind lipoproteins. These findings indicate that lipid components of HCV rather than E2 are mainly responsible for HCV-SR-BI binding. This idea was further strengthened by the observation that purified VLDL and ApoE inhibited HCV-SR-BI binding[[66](#_ENREF_66)]. Earlier indications that HCV-associated lipoproteins are involved in SR-BI attachment, rather than E2 itself, were reported by Maillard *et al*[[67](#_ENREF_67)]. They observed that SR-BI-binding of HCV from sera of infected patients was insensitive to anti-E2-HVR1 antibodies, whereas this interaction was inhibited by ApoE and VLDL.

The lipid transfer function of SR-BI is involved during post-attachment HCV entry. SR-BI has also been demonstrated to mediate post-binding events during HCV entry[[68](#_ENREF_68)]. Besides its primary HCV attachment function through HCV-associated ApoE, SR-BI is involved in HCV entry by means of its lipid transfer ability. Antibodies that inhibit HDL binding and SR-BI-mediated lipid transfer potently inhibit HCV infection of different genotypes both in cell culture and in humanized uPA-SCID mice[[69](#_ENREF_69),[70](#_ENREF_70)]. In addition to SR-BI-specific antibodies, small-molecule inhibitors of SR-BI-mediated cholesteryl ester lipid uptake (ITX-5061, ITX-7650, Rimcazole and BLT (block lipid transport)-2, 3 and 4) also have proven anti-HCV activity[[23](#_ENREF_23),[71-76](#_ENREF_71)]. However, it should be noted that besides their ability to block SR-BI-mediated lipid transfer, these molecules all abrogate the sE2-SR-BI interaction as well.

Increasing evidence for the role SR-BI’s lipid transfer function plays during HCV entry was provided by Thi *et al*[66]. These investigators showed that the inhibition of HCV pseudoparticle (HCVpp) entry in murine SR-BI expressing cells by BLT-4 correlated with the level of lipid transfer abrogation. Due to the inability of HCV E2 to bind murine SR-BI, this finding indicates the essential involvement of SR-BI’s lipid transfer function in mediating HCV entry in a process that is completely independent of E2’s attachment to and/or interaction with SR-BI. Additional proof of this concept was delivered by the observation that an HCVpp E2 mutant (L399R), unable to bind SR-BI, was still dependent on the presence of SR-BI for its infectivity. This mutant therefore used SR-BI for cell entry by other means than its E2 binding capacity. Furthermore, mouse SR-BI mutants, unable to bind E2 and impaired in their lipid transfer, reduced HCVpp infection proportional to their impairment of lipid transfer ability[[66](#_ENREF_66)]. In addition, anti-SR-BI mAbs have been reported that interfere specifically with post-binding steps during the HCV entry process linked to SR-BI’s lipid transfer function without affecting the SR-BI-E2 or SR-BI-HDL interactions[[77](#_ENREF_77)].

Post-attachment is SR-BI-E2 interaction. Although it appears increasingly unlikely that E2 is directly involved in SR-BI mediated primary attachment of HCV to the host cell, a functional role for E2 during the interaction of HCV with SR-BI should not be ignored. Indeed, Catanese *et al*[[78](#_ENREF_78)] identified residues in SR-BI that are involved in sE2 binding (AA 70-87 and residue E210), but these are distinct from the HDL binding site (C323[[79](#_ENREF_79)]). Mutations in this region that confer SR-BI defective for sE2 binding (however retaining its oligomerization, HDL binding and cholesterol efflux activity) impaired the ability of SR-BI to mediate HCV infection. This indicates that the E2 binding ability of SR-BI remains important for HCV infection[[78](#_ENREF_78)]. These observations convince us to believe that the ability of E2 to interact with SR-BI is not predominantly involved in primary HCV attachment but rather becomes important during a post-attachment process. Accordingly, the interaction of E2 with SR-BI is essential for the infection enhancement-process mediated by HDL (cfr. infra)[[66](#_ENREF_66)].

In conclusion, currently available data reveal three important SR-BI functions involved in HCV entry: (1) SR-BI-ApoE attachment; (2) SR-BI lipid transfer; and (3) SR-BI-E2 interaction. Altogether, it can be suggested that SR-BI functions as a primary HCV receptor that interacts with virus-associated lipoproteins before subsequent direct interactions occur with the HCV glycoprotein E2. Through its lipid transfer function, SR-BI may crucially facilitate the accessibility or the recruitment of the HCV receptor complex by membrane cholesterol enrichment. Finally, the ability of SR-BI to simultaneously interact with HDL and E2 might be essential for the support or even enhancement of HCV infection.

**LDL-receptor:** In their efforts to unravel the genetic defect in familiar hypercholesterolemia, Goldstein and Brown discovered the cell surface receptor for LDL, the LDL-receptor (LDL-R) (REF). This receptor transfers LDL particles into cells through clathrin-coated pits and vesicles before lysosomal degradation. Within the cell, LDL-derived cholesterol elicits several regulatory functions in cholesterol metabolism and homeostasis, including feedback inhibition of cholesterol synthesis[[80](#_ENREF_80)]. VLDL is not a ligand for LDL-R whereas its lipolytic remnants IDL and LDL, respectively resulting from sequential triglyceride hydrolysis catalyzed by LPL and HL[[33](#_ENREF_33)].

While HCV envelope glycoprotein E2 did not bind to LDL-R[[81](#_ENREF_81)], it was proposed to function as an HCV attachment/entry factor through interaction with HCV associated ApoE and ApoB[[60](#_ENREF_60)]. Indeed, LDL has been shown to compete with serum-derived HCV for LDL-R[[82](#_ENREF_82)]. In addition, Molina and co-workers demonstrated the involvement of LDL-R in HCV infection of primary hepatocytes[[83](#_ENREF_83)]. The virus is thought to hijack the ability of LDL-R to capture lipoproteins from the circulation for uptake of cholesterol into cells. This mechanism is not exclusive to Flaviviridae but may be a general feature among viruses that are associated with lipoproteins[[27](#_ENREF_27)]. However, LDL-R implication in the HCV life cycle has been controversial. Although it has been suggested that HCV infectivity is facilitated by interactions between HCV’s ApoE moiety and LDL-R[[84-86](#_ENREF_84)], recent data indicate that this is not necessarily the case. Prentoe *et al*[[87](#_ENREF_87)] observed that LDL-R antibodies interfering with ApoE- and ApoB-dependent LDL-R association blocked HCV infectivity less efficiently compared to LDL-R antibodies with lower interference of lipoprotein association. Furthermore, addition of exogenous LPL increased HCV binding to LDL-R, which increased HCV RNA internalization but reduced HCV infectivity[[88](#_ENREF_88)]. These data encourage us to speculate that HCV can indeed interact with LDL-R but this event does not necessarily lead to a productive infection. Since LDL-R blocking studies clearly assigned a supporting role for LDL-R in the life cycle of HCV, we assume that this function must be distinct from its lipoprotein binding capacities. Interestingly, recent work from Albecka *et al*[[88](#_ENREF_88)] confirms a role for LDL-R in the life cycle of HCV but indicates that it is mainly involved in viral replication rather than supporting productive HCV entry. In summary, the function of LDL-R during the HCV life cycle seems double-edged: (1) inhibition of infection through HCV-associated lipoprotein recognition, which supposedly paves the way to non-productive HCV entry; and (2) support of infection by enhancing replication.

**NPC1L1:** The most recently described host cell protein that modulates HCV cell entry is the Niemann-Pick C1–like 1 cholesterol uptake receptor (NPC1L1)[[89](#_ENREF_89)]. NPC1L1 is a 13-transmembrane-domain cell surface cholesterol-sensing receptor expressed on the apical surface of intestinal enterocytes and the bile canalicular membrane of human hepatocytes[[90](#_ENREF_90)]. It is critical for intestinal cholesterol absorption[[91](#_ENREF_91)] and regulation of biliary cholesterol concentration[[92](#_ENREF_92)]. Probably, the cholesterol uptake activity of NPC1L1 is involved in HCV entry. Antibody-mediated receptor blockade of NPC1L1 large extracellular loop 1 (LEL1), but not LEL 2 or LEL3, and NPC1L1 silencing impairs HCVcc infection initiation. Ezetimibe, a 2-azetidinone-class NPC1L1 antagonist that has been approved by the FDA as a cholesterol-lowering medicine[[93](#_ENREF_93)] inhibits HCV uptake of all major genotypes *in vitro* at a post-binding step and delays genotype 1b infection in humanized mice[[89](#_ENREF_89)].

**HSPG, LPL and hepatic triglyceride lipase:** Although LPL exerts its physiological action at the luminal surface of for example cardiac, muscle and adipose tissue endothelial cells, it is found to be synthesized by parenchymal cells and thought to be translocated to its site of action afterwards. LPL is a secretory water-soluble protein that belongs to the triglyceride lipase family and has triacylglycerol hydrolase activity that targets lipoproteins such as chylomicrons and VLDL through their ApoCII moiety. By hydrolyzing the triacylglycerol component, LPL provides fatty acids to peripheral tissues and therefore plays a central role in overall lipid metabolism. In addition, LPL has a non-catalytic function based on its heparin- and lipoprotein-binding domains, which enables it to form a bridge between lipoproteins and cell surface HSPG, especially with strong ligand affinity to hepatocyte HSPG (syndecan-1). Since HCV particles are tightly associated to lipoproteins, hepatocyte HSPG has been proposed as a possible attachment receptor for HCV[[94-96](#_ENREF_94)]. In addition, ApoE has been implicated in virus attachment to the host cell by an interaction that involves cell surface HSPG, in particular syndecan-1[[97](#_ENREF_97),[98](#_ENREF_98)].

Although extrahepatically expressed, peripheral LPL was shown to be an important component of lipoproteins capable of mediating their binding to hepatic receptors and, thereby targeting lipoproteins to the liver for internalization and degradation in hepatocytes[[34](#_ENREF_34),[99](#_ENREF_99),[100](#_ENREF_100)]. As it is involved in hepatic clearance of lipoproteins from the circulation, LPL’s role has been investigated in HCV cell entry. It was observed that exogenous LPL indeed mediates cellular binding of HCV through HCV-associated lipoproteins in an HSPG-dependent manner. These findings suggest an indirect interaction of HCV with HSPG, through LPL. As mentioned however, while LPL enhances HCVcc binding to hepatoma cells, it actually decreases HCV infectivity[[88](#_ENREF_88),[101](#_ENREF_101),[102](#_ENREF_102)].

Different mechanisms can be proposed to explain this abortive LPL-dependent infection process. LPL could mediate hepatic lipoviral clearance either by means of its lipoprotein bridging abilities to liver HSPG (syndecan-1), that leads to direct endocytosis through the HSPG-metabolic pathway and degradation of HCV[[101](#_ENREF_101)], or alternatively by its lipolytic activity, or by a combination of both. The enzymatic activity of LPL could transform HCV-associated lipoproteins into lipoprotein remnants that facilitate virus binding to LDL-R, also a non-productive HCV entry pathway[[88](#_ENREF_88),[103](#_ENREF_103)]. Finally, using electron microscopy Maillard *et al*[[102](#_ENREF_102)] provided evidence for infectivity inhibition by retention of the viral particle at the cell surface, rather than non-productive cellular uptake, that depended on both LPL-mediated lipolytic modification of the viral lipoprotein content and its strong bridging effect.

As mentioned, LPL is a non-hepatically expressed triglyceride lipase, mainly involved in converting VLDL to IDL and LDL. Another enzyme catalyzing IDL to LDL conversion is the hepatically expressed hepatic triglyceride lipase (HTGL). Modification of HCVcc-associated lipoproteins exerted by these lipases, resulted in a decreased amount of HCV-associated ApoE and HCV of higher density, which caused loss of HCV infectivity. HTGL blockade partially neutralized LPL-mediated infection inhibition and its knockdown even increased HCV infectivity[[103](#_ENREF_103)]. Altogether, these observations tempt us to hypothesize that interactions with lipases can target the lipoviroparticle to an abortive entry pathway that involves LDL-R and/or HSPG.

***Lipid receptor ligands influence HCV entry***

Several SR-BI receptor ligands have been reported to alter HCV infectivity; HDL enhances HCV entry (see next paragraph) whereas VLDL, LDL, oxidized LDLand amyloid-α have inhibitory effects. OxLDL presumably inhibits HCV infection by two different mechanisms. First, it affects the biophysical properties of the viral particle; and second it perturbs the interaction between HCV and SR-BI in a non-competitive manner[[104](#_ENREF_104),[105](#_ENREF_105)]. Serum amyloid A, an acute phase protein and SR-BI receptor ligand, was also shown to possess anti-HCV activity by interacting with the viral particle[[106](#_ENREF_106),[107](#_ENREF_107)].

Both LDL and VLDL reduce infectivity of HCVpp[[23](#_ENREF_23),[108](#_ENREF_108)]. VLDL inhibits HCVcc probably by abrogating the binding between virus associated ApoE and SR-BI[[66](#_ENREF_66)]. To some degree, LDL also inhibits SR-BI interaction with HCV from serum of infected patients but less efficiently than VLDL[[67](#_ENREF_67)]. Accordingly, LDL and VLDL outcompete serum-derived lipoviroparticle binding to hepatocyte cell lines[[60](#_ENREF_60)]. LDL has also been shown to compete with serum-derived HCV for LDL-R[[82](#_ENREF_82)].

***HDL enhances HCV infection***

Different groups reported that infectivity of HCVcc and HCVpp in cell culture is enhanced by the presence of human serum, in which the HDL component was identified as the responsible agent[[23-25](#_ENREF_23),[69](#_ENREF_69),[72](#_ENREF_72),[73](#_ENREF_73),[108](#_ENREF_108),[109](#_ENREF_109)]. It was discovered that the HVR1 region of E2 is particularly important for this process, since HVR1 deletion or mutations in this region greatly hamper the infection enhancement ability of HDL. Accordingly, we observed that HVR1 deletion or other mutations in the envelope glycoproteins that alter HCV’s SR-BI-dependency for viral entry render these viruses unable to benefit from HDL-mediated infection enhancement[[110](#_ENREF_110)]. SR-BI is indeed the host cell factor supporting this phenomenon. This is endorsed by the observations that HDL-mediated infection enhancement can be abolished by both small-molecule inhibitors of SR-BI’s lipid transfer[[23](#_ENREF_23),[72](#_ENREF_72),[73](#_ENREF_73)] and mutations in SR-BI that reduce its lipid transfer function[[109](#_ENREF_109)]. However, besides lipid transfer abrogation, these receptor mutations and small molecule inhibitors also decreased the binding potential of sE2 to SR-BI, making it impossible to discriminate the involvement of these two receptor functions in the enhancing process. Thi *et al*[[66](#_ENREF_66)] recently confirmed the essential role of the E2 binding function of SR-BI in this context. They observed that mouse SR-BI, which has functional lipid transfer activity but lacks E2 binding properties, did not allow HDL to enhance HCV infectivity. In addition, HDL did not enhance cell entry of HCVpp harboring SR-BI binding defective E2.

Since, to our knowledge, it has never been shown that HDL infection enhancement solely relies on the ability of SR-BI to interact with E2, independent of SR-BI’s lipid transfer, we propose a concerted action of both receptor functions in this process. We postulate that the critical E2-SR-BI interaction positions the HCV viral particle in such a way that it significantly benefits from SR-BI’s lipid transfer, leading to infection enhancement. By promoting the SR-BI mediated lipid transfer, HDL could either change cholesterol contents of the lipoviroparticle itself or initiate cholesterol enrichment of the host cell plasma membrane resulting in facilitation of post-attachment entry events. It has indeed been reported that HCV entryis dependent on the cholesterol content of the host cell membrane[[111](#_ENREF_111)]. Possibly, cholesterol-mediated elevated plasma membrane fluidity assists and accelerates essential events in the HCV entry process such as receptor recruitment and interactions, particle internalization and fusion. Of note, HDL does not stimulate HCVpp or sE2 binding to CD81 or SR-BI, and no indication for direct interactions between HDL and HCVpp have been observed[[73](#_ENREF_73),[112](#_ENREF_112)].

**Increased receptor recruitment and interactions:** E2-specific antibodies do not abrogate HCV binding to SR-BI, yet they neutralized infectivity of HCV particles of all densities[[66](#_ENREF_66)]. Although E2 is therefore not involved in primary HCV-SR-BI attachment, it does mediate HCV cell entry by enabling HDL to enhance its infectivity and through interaction with more downstream entry factors. It is observed that the HVR1 region of E2 masks the viral binding site to CD81[[113](#_ENREF_113)], the central regulator of HCV entry[[114](#_ENREF_114)]. Possibly by inducing a conformational change to the viral envelope, HCV-E2-SR-BI interaction activates the virus for CD81 receptor engagement. A kinetic analysis of HCVcc entry illustrated that SR-BI acts at an early step in the infection process closely linked to the interactions of the virus with CD81 and CLDN1 suggesting that HCV entry may be mediated through the formation of co-receptor complexes[[68](#_ENREF_68),[115](#_ENREF_115)]. Additional evidence for co-receptor complex formation between CD81 and CLDN1 was demonstrated using FRET analysis[[116](#_ENREF_116)].

SR-BI localizes to cholesterol-enriched plasma membrane microdomains[[117](#_ENREF_117)] where also tetraspanins such as CD81 associate with each other, with other tetraspanin and with nontetraspanin proteins. These associations are modulated by cholesterol[[118](#_ENREF_118),[119](#_ENREF_119)]. Therefore, SR-BI/HDL mediated cholesterol enrichment of the plasma membrane could increase the efficiency of co-receptor complex formation. For this reason, the SR-BI-HDL-HCV interaction should act in concert with downstream HCV receptors. CD81 is indeed required for SR-BI/HDL-mediated HCV entry enhancement since silencing of CD81 expression abolished this process[[68](#_ENREF_68)]. In addition, CD81 and SR-BI cooperatively mediate HCV infection, and this is dependent on membrane cholesterol content[[111](#_ENREF_111)]. Cellular cholesterol depletion also decreased HCV infectivity by reducing CLDN1 localization, CLDN1-CD81 and CD81-CD81 association at the plasma membrane[[120](#_ENREF_120)]. Furthermore, SR-BI and CD81 mutants defective for receptor palmitoylation, which is essential for their partitioning in cholesterol-rich microdomains, reduced HCV entry[[109](#_ENREF_109),[121](#_ENREF_121)]. Hydrolysis of sphingomyelin, another important plasma membrane lipid constituent, reduced HCV entry by decreasing CD81 cell surface levels[[122](#_ENREF_122)]. Altogether, these observations emphasize that the function of HCV cell entry factors strongly depends on specific membrane lipid contents. Therefore, it can be assumed that these HCV receptor associations benefit from SR-BI/HDL-mediated cholesterol delivery.

**Accelerated particle internalization:** HDL-mediated HCVpp and HCVcc entry acceleration has been observed[[24](#_ENREF_24),[73](#_ENREF_73)]. HDL accelerates HCV endocytosis by reducing the time that viral particles are cell-bound before being internalized[[73](#_ENREF_73)]. This pre-internalization phase may reflect the time needed to form HCV receptor complexes, a process that likely benefits from SR-BI/HDL-mediated cholesterol delivery (cfr supra). This is in agreement with the rate-limiting role fulfilled by SR-BI in HCV entry[[123](#_ENREF_123),[124](#_ENREF_124)].

**Increased fusion:** After formation of the HCV-receptor complex, HCV utilizes clathrin-dependent receptor mediated endocytosis to enter cells. Of note, the function of these specialized cholesterol-enriched plasma membrane domains, clathrin-coated pits, is also dependent on membrane cholesterol levels[[125](#_ENREF_125)]. The internalization step of endocytosis involves the budding of vesicles from the plasma membrane, which are then targeted to and fused with an early endosomal compartment. In the early endosome, acidification probably induces a conformational change in the E1E2 glycoproteins, after which the viral envelope fuses with the endosomal membrane, thereby releasing the viral nucleocapsid into the cytoplasm[[126](#_ENREF_126),[127](#_ENREF_127)]. This fusion process is significantly facilitated by the presence of cholesterol and sphingomyelin in the target membrane[[128](#_ENREF_128),[129](#_ENREF_129)] and ApoCI, an exchangeable apolipoprotein that predominantly resides in HDL, on the viral membrane[[112](#_ENREF_112)]. Since HDL did not directly interact or exchange ApoCI with HCV, the authors propose a mechanism for ApoCI exchange mediated by a close interaction of HDL with HCV at their common receptor, SR-BI[[112](#_ENREF_112)]. We hypothesize that this exchange depends on a correct approximation of HCV with HDL, mediated by an intact SR-BI-E2 interaction that is essential for HDL-mediated infection enhancement.

***Effects on viral RNA replication***

Genomic HCV RNA replication[[130](#_ENREF_130)] has also been linked to lipid metabolism[[131](#_ENREF_131)]. Changes in hepatocyte lipid content could therefore affect the replication of the HCV genome. Indeed, an anti-LDL-R mAb decreased HCV RNA replication by altering intracellular lipid content[[88](#_ENREF_88)]. For example decreased free/esterified cholesterol and phospatidylcholine/phospatidylethanolamine ratios were observed[[88](#_ENREF_88)]. Of particular interest is the latter ratio of membrane phospholipids which, when decreased, has been linked to steatohepatitis. A decrease of this phospholipid ratio affects endoplasmic reticulum membrane integrity where HCV replication takes place[[132](#_ENREF_132)]. In addition, the HCV polymerase, NS5B, contains a sphingolipid binding motif and a sphingolipid biosynthesis inhibitor was found to block HCV replication[[133](#_ENREF_133)]. Finally, the lipid kinase phosphatidylinositol 4-kinaseIIIα (PI4KIIIα) was shown to be a host cofactor essential for efficient HCV replication by supporting the formation of the membranous web, an altered membrane structure specialized in HCV RNA replication[[134](#_ENREF_134),[135](#_ENREF_135)].

***Effects on assembly and secretion***

**Lipid droplets establish an HCV production microenvironment:** The lipid droplet (LD) is an organelle used for the storage of neutral lipids and the maintenance of intracellular lipid homeostasis. LDs consist of a core of triglycerides and cholesteryl esters, surrounded by a phospholipid monolayer and associated proteins. It moves through the cytoplasm where it can interact with the endoplasmic reticulum, thereby facilitating lipid and protein transport to other organelles. In addition, cell signaling and trafficking events have been linked to LDs[[136](#_ENREF_136)].

Moradpour *et al*[137] found that HCV core protein is located on the endoplasmic reticulum membrane and on the surface of cytoplasmic LDs[[138](#_ENREF_138)]. Moreover, it was shown that LD-association of HCV proteins is essential for production of infectious HCV particles. HCV core proteins on the LDs seem to induce endoplasmic reticulum derived LD-associated membrane rearrangements. These rearrangements might establish an HCV production microenvironment recruiting HCV RNA and non-structural proteins around LDs[[139](#_ENREF_139)]. In addition, the HCV core protein induces LD overproduction which might be linked to steatosis and abnormal lipid metabolism caused by chronic HCV infection[[140](#_ENREF_140)]. Besides lipid storage, the LD is involved in the lipoprotein secretory pathway[[141](#_ENREF_141)], which is found to intersect with the HCV assembly process[[142](#_ENREF_142)].

**HCV secretion intersects with the VLDL secretory pathway:** The first step in the VLDL assembly process involves co-translational lipidation of ApoB-100, the main protein component of VLDL. Thereto, microsomal triglyceride transfer protein (MTP) interacts with ApoB100 to deliver lipidsfrom LDs into the endoplasmic reticulum lumen*.* Additional lipidation results in atriglyceride-poor form of VLDL. After transportation to the Golgi apparatus, depending on the triglyceride level, it can either be secreted as such or further lipidated, and associated to other apolipoproteins such as ApoE, into mature triglyceride-rich VLDL by fusing with bulk lipids from luminal LDs[[141](#_ENREF_141)].

HCV and VLDL are both uniquely secreted by hepatocytes and circulate in blood associated to each other[[60](#_ENREF_60),[61](#_ENREF_61),[143](#_ENREF_143)]. This complexation likely occurs during viral particle assembly and release, processes found to intersect with VLDL assembly and secretion pathways. On isolated membrane vesicles containing the HCV replication complex, Huang *et al*[[142](#_ENREF_142)] observed enrichment of proteins involved in VLDL assembly, such as ApoB, ApoE and MTP. In addition, HCV production was reduced by VLDL assembly blockade using ApoB silencing and MTP inhibition[[142](#_ENREF_142),[144](#_ENREF_144),[145](#_ENREF_145)]. These findings, together with the observation that infectious intracellular precursors of HCV have a higher buoyant density compared to secreted HCV[[146](#_ENREF_146),[147](#_ENREF_147)] argues for a lipidation of HCV during a maturation process that parallels VLDL formation. Additional evidence for the overlap of HCV and VLDL assembly processes is provided by the work of Icard *et al*[[148](#_ENREF_148)]. They detected HCV glycoproteins in ApoB containing triglyceride rich lipoproteins when expressed in Caco-2 and HepG2 cells, but not in Huh7 hepatoma cells, an event that was prevented by MTP inhibition. Moreover, HCV is thought to divert cellular processes towards its own generation, which is detrimental to the hepatocyte’s VLDL production. An HCV-induced deficiency in arylacetamide deacetylase (AADAC), an enzyme involved in VLDL production by lipolysis of triacylglycerol from LDs, was identified to cause VLDL production impairment during the early peak of HCV infection in culture[[149](#_ENREF_149)].

Besides MTP and ApoB, ApoE is essential during VLDL and HCV production. Fazio *et al*[[150](#_ENREF_150)] demonstrated that ApoE is not exclusively important for lipoprotein uptake alone, but it can be recycled to be involved in lipoprotein assembly as well. Interestingly, its knockdown hampers the production of infectious HCV particles[[151](#_ENREF_151),[152](#_ENREF_152)]. Production of secreted infectious HCV was very poorly restored after ectopic expression of an ApoE mutant that is unable to be secreted; infectious HCV particles accumulated intracellularly instead[[86](#_ENREF_86)]. It should be noted that Jiang *et al*[[152](#_ENREF_152)], emphasize the importance of ApoE during HCV production but show that ApoB inhibition does not affect this process. They attribute the effect of MTP inhibitors on HCV production suppression to its inhibitory consequences on ApoE expression rather than its blockade of ApoB lipidation. Accordingly, production of HCV from non-liver cells depends on ectopic expression of ApoE[[153](#_ENREF_153)] and not ApoB or MTP[[154](#_ENREF_154)]. ApoE interacts with HCV nonstructural protein 5A (NS5A) that is involved in HCV production. Hence assembly-defective HCV mutants had strongly impaired ApoE-NS5A binding[[152](#_ENREF_152),[155](#_ENREF_155)]. ApoE is suggested to be involved in an assembly step that acts between capsid envelopment and secretion of infectious HCV[[154](#_ENREF_154)].

**Apolipoproteins and lipids are HCV particle constituents:** While the requirement of ApoB for HCV assembly is controversial, ApoB-containing lipoviroparticles have been identified in patients[[60](#_ENREF_60)]. Although VLDL and both anti-ApoB and ApoE block serum derived lipoviroparticle binding to hepatocyte cell lines[[60](#_ENREF_60)], only VLDL and anti-ApoE can efficiently compete them out for interaction with SR-BI[[67](#_ENREF_67)]. The presence of ApoE on the viral particle is confirmed in different reports and is assigned a very important function in HCV entry, especially since ApoE specific antibodies neutralize HCV infectivity[[84](#_ENREF_84),[151](#_ENREF_151),[156](#_ENREF_156)]. As mentioned, ApoE, rather than HCV glycoprotein E2, is involved in primary attachment of HCV to SR-BI[[66](#_ENREF_66),[67](#_ENREF_67)]. In addition, ApoE is involved in direct cell-to-cell transmission[[154](#_ENREF_154)] and the loss of HCV associated ApoE, after LPL treatment, resulted in decreased HCV infectivity[[103](#_ENREF_103)].

ApoCI, an exchangeable apolipoprotein that predominantly resides in HDL, has been identified as a component of the HCV viral particle[[157](#_ENREF_157)]. While ApoCI is not a minimal requirement for HCV assembly[[154](#_ENREF_154)], its association occurs within the cell prior to virus release[[157](#_ENREF_157)]. Like HDL, pre-incubation of HCVpp with ApoCI resulted in a genotype-independent enhancement of infection. The observation that anti-ApoCI suppressed the HDL-mediated infection enhancement further suggests that ApoCI is a key mediator of this process[[108](#_ENREF_108),[112](#_ENREF_112),[157](#_ENREF_157)]. As mentioned, ApoCI enhances HCV infectivity by specifically promoting HCV fusion. It should be noted that higher concentrations of ApoCI inhibited HCVpp infectivity by specifically disrupting the viral membrane[[112](#_ENREF_112)].

In support of the tight association with lipoproteins, it was observed that the lipid composition of HCV particles is strikingly different from cell membranes, but its increased ratio of cholesteryl esters-to-phospholipids rather resembles that of LDL and VLDL[[156](#_ENREF_156)]. Furthermore, the association of cholesterol and sphingolipids with HCV is essential for cell internalization, virus maturation and infectivity[[158](#_ENREF_158),[159](#_ENREF_159)]. In addition, HCV-associated cholesterol might contribute to the virion’s interaction with ApoE, since cholesterol-extracted HCVcc showed dramatically reduced reactivity with anti-ApoE[[159](#_ENREF_159)].

**Effect of lipoproteins on antiviral efficacy of anti-HCV and anti-receptor antibodies**

***Effect of lipoproteins on escape from anti-HCV neutralizing Abs***

**HCV-associated lipoproteins:** Lipoproteins associated to virus particles could mask neutralizing epitopes, thereby facilitating viral escape from the humoral immune response. Besides viral components, cell entry of HCV is initiated and mediated by endogenous proteins providing a mechanism of escape from the humoral immune response. Indeed, HCV uses associated host lipoprotein components to attach to lipid receptors on the hepatocyte. This explains, at least partially, the inefficiency of anti-envelope antibodies to prevent primary hepatocyte attachment of HCV and to neutralize HCV infectivity[[66](#_ENREF_66),[67](#_ENREF_67)]. Indeed, it has been postulated that virus-lipoprotein interactions play a role in immune evasion[[60](#_ENREF_60)]. Some evidence has been obtained to support this hypothesis. It was observed that HCV particles of lower density are more resistant to neutralizing antibodies, a feature that might however be specific for gt2a virus only[[160-162](#_ENREF_160)]. In addition, serum-derived HCV particles have been observed that were seemingly totally bound to beta-lipoprotein, a condition that coincided with the absence of HCV-IgG complexes, suggesting that virus associated lipoproteins may restrict the access of anti-envelope antibodies[[163](#_ENREF_163)].

Previous studies have indicated a role for HVR1 and E2 residue 451 in covering the CD81 binding site, shielding neutralizing epitopes and infectivity of low density viral particles[[113](#_ENREF_113),[160](#_ENREF_160)]. In addition, Tao and coworkers described a mutant (I414T) with increased susceptibility to E2 neutralizing Abs. Although prior to release, no difference in neutralization behavior was observed between mutant and wild type virus, the latter became more resistant to neutralization upon cell secretion. This observation was attributed to increased ApoE and ApoCI abundance on the viral particle[[147](#_ENREF_147)]. Accordingly, HCV production in ApoE knockdown cells generates viral particles with increased sensitivity to neutralization[[164](#_ENREF_164)]. In addition, a correlation was observed between ApoE association and the ability of a viral isolate to escape from neutralizing antibodies and infect the liver graft after liver transplantation[[164](#_ENREF_164)]. This might explain viral quasispecies evolution during liver transplantation. Clinical virus isolates selected during the liver transplantation process were indeed characterized by enhanced viral entry and escape from neutralizing antibodies compared to non-selected variants[[165](#_ENREF_165)].

We hypothesize that the interaction of HCV-associated ApoE with the host cell receptor SR-BI initiates changes to the viral particle by altering its lipid content, mediated by SR-BI’s lipid transfer activity. Alternatively, the ApoE-SR-BI interaction could precede and direct E2 presentation to SR-BI, which in turn initiates a conformational change in E2. These modifications might result in exposing CD81 binding sites and neutralizing epitopes in E2. This gradual epitope exposure could be a system used by HCV to preclude neutralizing antibody recognition and might be needed for E2 to interact with the downstream receptor CD81. It has indeed been suggested that CD81 binding epitopes are not yet exposed on circulating particles[[81](#_ENREF_81),[166](#_ENREF_166),[167](#_ENREF_167)]. This implies that anti-E2 antibodies interfering with E2-CD81 interactions may only exert their neutralizing activity from the moment of epitope exposure after SR-BI docking until the interaction with the downstream coreceptor complex. Importantly, HDL reduces this time window presumably by facilitating receptor complex formation[[73](#_ENREF_73)].

**Virus-free lipoproteins:** As mentioned before, HDL is able to enhance HCV infectivity via the SR-BI lipid transfer and E2 binding function. It was observed that HDL reduces the lag between HCV-host cell binding and its actual internalization. This might reflect a reduction in the time needed to form a functional receptor complex and the time needed for viral glycoprotein E2 to engage with CD81. Therefore, HDL can reduce the antiviral efficiency of molecules blocking these interactions by shortening the time window during which such molecules are active. In fact, the virus might use this entry acceleration to escape humoral immune responses that target this virus-host factor interaction[[73](#_ENREF_73)]. This was confirmed by a kinetic analysis revealing that HCVpp entry enhancement by HDL is initiated earlier than the activity of neutralizing antibodies[[24](#_ENREF_24)]. Accordingly, by enhancing HCV entry, HDL lowers the neutralization efficacy of such anti-HCV antibodies. This neutralization attenuation effect was specifically observed for antibodies interfering with the E2-CD81 interaction (such as AP33, 3/11 and H48) and was not observed for polyclonal anti-E1 or an antibody with slower neutralization kinetics that interfered with E2-SR-BI (designated 9/27)[[24](#_ENREF_24),[73](#_ENREF_73)]. In addition, antibodies isolated from HCV-infected patients also suffer from reduced neutralization efficacy in the presence of human serum or HDL[[23-25](#_ENREF_23)]. Inhibition of SR-BI’s lipid transfer restores neutralization by anti-HCV antibodies in the presence of human serum[[23](#_ENREF_23),[24](#_ENREF_24),[73](#_ENREF_73)]; resistance to neutralization by an anti-E2 neutralizing Ab (C1) correlated with increased SR-BI expression levels[[123](#_ENREF_123)]; and, the neutralizing activity of patient sera increased with lower SR-BI levels[[24](#_ENREF_24)]. These observations indicate that SR-BI is the responsible factor, activated by HDL, for neutralization attenuation of anti-HCV antibodies. In conclusion, although antibodies that bind to the viral envelope, and thereby interfere with receptor interactions, are able to neutralize HCV infection, SR-BI/HDL interactions accelerate the entry of HCV particles that are not yet neutralized. This process therefore might help the virus to persist in patients. Indeed, persisting viral strains were more efficiently facilitated by serum than those that were controlled during the acute phase[[25](#_ENREF_25)].

***Effect of lipoproteins on escape from anti-receptor Abs***

**Anti-CD81 antibodies:** Another class of HCV entry inhibitors that interfere with CD81 and E2 interactions are CD81-receptor blockers. If this receptor blocker is not present before the virus initiates its entry, HDL could again reduce its antiviral efficacy by shortening the window of effective antiviral activity. Accordingly, HCV infection inhibition using an anti-CD81 mAb, designated JS81, was strongly reduced when added during infection in the presence of human serum[[73](#_ENREF_73)]. Once more, the attenuation of anti-CD81 antiviral efficacy was alleviated by blocking SR-BI, indicating that compounds that block E2-CD81 interaction are less potent when SR-BI is activated. The same antibody was effective in preventing HCV infection in a human-liver chimeric mouse model, but was unable to resolve infection when administered shortly (six hours to three days) after viral challenge[[70](#_ENREF_70),[168](#_ENREF_168)]. This again highlights the importance of CD81 receptor blocker availability before exposure to the virus.

**Anti-SR-BI antibodies:** In contrast to CD81 receptor blockade, the timing of SR-BI inhibition seems less delicate since administration of anti-SR-BI mAb therapy three days after HCV inoculation still successfully protects humanized mice from infection[[70](#_ENREF_70),[169](#_ENREF_169)]. Accordingly, we have shown that this therapy effectively inhibits direct cell-to-cell transmission, hence indicating that it exerts its antiviral activity even after the primary infection is established. Therefore, compared to anti-CD81 therapy, it appears that the time frame after infection during which the anti-SR-BI therapy remains effective is significantly larger. As mentioned, HDL reduces the antiviral efficacy of molecules interfering with CD81-E2 interactions by shortening the time window during which such molecules are active[[73](#_ENREF_73)]. In contrast, it was shown that HDL did not negatively affect anti-SR-BI’s antiviral efficacy[[69](#_ENREF_69)]. Moreover, we observed that human HDL positively influences the ability of an anti-SR-BI specific antibody, mAb1671, to inhibit HCV infectivity[[110](#_ENREF_110)]. Addition of *in vivo*-like concentrations of human HDL to anti-SR-BI mAb1671 in the HCV cell culture system significantly increases its antiviral efficacy, enabling almost complete infection inhibition. This observation might explain why the antibody reaches higher protection levels in humanized mice than it does in the HCV cell culture system; and why it has a larger therapeutic window compared to anti-CD81 *in vivo*. Of note, anti-SR-BI small molecule ITX-5061’s antiviral efficacy was not increased by the addition of *in vivo*-like concentrations of human HDL in the HCV cell culture system.

**Conclusion**

As mentioned, today no anti-HCV therapy is approved for prevention of re-infection after liver transplantation. Interestingly, anti-SR-BI therapy was strongly protective in humanized mice after exposure to a serum-derived viral variant that escaped the control of the adaptive immune response and became dominant after liver transplantation[[165](#_ENREF_165),[169](#_ENREF_169)]. These variants have an increased entry phenotype and escape more easily from envelope neutralizing antibodies, possibly due to increased HCV-ApoE associations[[164](#_ENREF_164)]. These data suggest that SR-BI receptor blockade may be a novel therapeutic approach to prevent graft reinfection in liver transplant patients. Furthermore, since active SR-BI was shown to be the responsible factor for HDL-mediated infection enhancement and reduced efficacy of anti-CD81 and anti-E2 neutralizing Abs, SR-BI inhibitors might increase their antiviral efficacy *in vivo*. Although HCV variants have been described that are more resistant to anti-SR-BI therapy in culture, these variants remain fully responsive to anti-SR-BI therapy in humanized mice[[110](#_ENREF_110)]. These observations encourage us to speculate that combinations of anti-SR-BI with anti-E2 antibodies might be worth the considering in the context of liver transplantation.

**Acknowledgments**

AAM is a recipient of a PhD Fellowship provided by the Egyptian government. We also want to thank Ms. Julie Vercauteren for graphical assistance.

**References**

1 **Zeuzem S**. Interferon-based therapy for chronic hepatitis C: current and future perspectives. *Nat Clin Pract Gastroenterol Hepatol* 2008; **5**: 610-622 [PMID: 18838975 DOI: 10.1038/ncpgasthep1274]

2 **Sarrazin C**, Hézode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. *J Hepatol* 2012; **56** Suppl 1: S88-100 [PMID: 22300469 DOI: 10.1016/S0168-8278(12)60010-5]

3 **Manns M**, Marcellin P, Poordad FPF, de Araujo ESA, Buti M, Horsmans Y, Janczewska EJE, Villamil F, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. Simeprevir (Tmc435) with Peginterferon/Ribavirin for Treatment of Chronic Hcv Genotype-1 Infection in Treatment-Naive Patients: Results from Quest-2, a Phase Iii Trial. *J Hepatol* 2013; **58**: S568-S568

4 **Lawitz E**, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* 2013; **368**: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]

5 **Peveling-Oberhag J**, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. *Med Microbiol Immunol* 2010; **199**: 1-10 [PMID: 19902246 DOI: 10.1007/s00430-009-0131-8]

6 **Charlton M**. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. *Hepatology* 2011; **54**: 3-5 [PMID: 21710471 DOI: 10.1002/hep.24470]

7 **Curry MP**, Forns X, Chung RT, Terrault N, Brown RS, Fenkel JM, Gordon FD, O'Leary JG, Kuo A, Schiano TD, Everson GT, Schiff ER, Befeler A, McHutchison JG, Symonds WT, Denning JM, McNair L, Arterburn S, Moonka D, Gane EJ, Afdhal NH. Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation. *Hepatology* 2013; **58**: 314a-315a

8 **Charlton MR**, Gane EJ, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman LW, Muir AJ, McHutchison JG, Symonds WT, Denning JM, McNair L, Arterburn S, Terrault N, Samuel D, Forns X. Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study. Hepatology 2013; **58**: 1378a-1378a

9 **Forns X**, Fontana RJ, Moonka D, McHutchison JG, Symonds WT, Denning JM, McNair L, Chang P, Kivett VA, Shiffman ML, Charlton MR. Initial Evaluation of the Sofosbuvir Compassionate Use Program for Patients with Severe Recurrent HCV Following Liver Transplantation. *Hepatology* 2013; **58**: 732a-733a

10 **Kwo P**, Mantry P, Coakley E, Te H, Vargas H, Brown R, Gordon F, Levitsky J, Terrault N, Burton J, Xie W, Setze C, Badri P, Vilchez R, Forns X. Results of the phase 2 study M12-999: Interferon-free regimen of ABT-450/r/ABT-267 ABT-333 ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. *J Hepatol* 2014; **60**: s47-s48 [DOI: 10.1016/S0168-8278(14)60116-1]

11 **Vercauteren K**, Leroux-Roels G, Meuleman P. Blocking HCV entry as potential antiviral therapy. *Future Virol* 2012; **7**: 547-561 [DOI: 10.2217/Fvl.12.47]

12 **Keck ZY**, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. *Curr Top Microbiol Immunol* 2008; **317**: 1-38 [PMID: 17990788 DOI: 10.1007/978-3-540-72146-8\_1]

13 **Chapel HM**, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. *Clin Immunol* 2001; **99**: 320-324 [PMID: 11358426 DOI: 10.1006/clim.2001.5036]

14 **Pestka JM**, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc Natl Acad Sci USA* 2007; **104**: 6025-6030 [PMID: 17392433 DOI: 10.1073/pnas.0607026104]

15 **Farci P**, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. *Proc Natl Acad Sci USA* 1996; **93**: 15394-15399 [PMID: 8986822 DOI: 10.1073/pnas.93.26.15394]

16 **Vanwolleghem T**, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, Purcell RH, Leroux-Roels G. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. *Hepatology* 2008; **47**: 1846-1855 [PMID: 18452146 DOI: 10.1002/hep.22244]

17 **Meuleman P**, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. *Hepatology* 2011; **53**: 755-762 [PMID: 21319203 DOI: 10.1002/hep.24171]

18 **Morin TJ**, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. *PLoS Pathog* 2012; **8**: e1002895 [PMID: 22952447 DOI: 10.1371/journal.ppat.1002895]

19 **Willems B**, Ede M, Marotta P, Wall W, Greig P, Lilly L, Kneteman N, Wong WN, Roy A, Marleau D, Scudamore C, Yoshida E, Rinfret A. Anti-HCV human immunoglobulins for the prevention of graft infection in HCV-related liver transplantation, a pilot study. *J Hepatol* 2002; **36**: 32-32 [DOI: 10.1016/S0168-8278(02)80095-2]

20 **Davis GL**, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Gnann JW. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. *Liver Transpl* 2005; **11**: 941-949 [PMID: 16035063 DOI: 10.1002/lt.20405]

21 **Schiano TD**, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, Eren R, Dagan S, Graham N, Williams PV, Andrews J. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. *Liver Transpl* 2006; **12**: 1381-1389 [PMID: 16933235 DOI: 10.1002/lt.20876]

22 **Chung RT**, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, Markmann JF, Hertl M, Pomposelli JJ, Pomfret EA, Florman S, Schilsky M, Broering TJ, Finberg RW, Szabo G, Zamore PD, Khettry U, Babcock GJ, Ambrosino DM, Leav B, Leney M, Smith HL, Molrine DC. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. *Am J Transplant* 2013; **13**: 1047-1054 [PMID: 23356386 DOI: 10.1111/ajt.12083]

23 **Bartosch B**, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. *J Virol* 2005; **79**: 8217-8229 [PMID: 15956567 DOI: 10.1128/JVI.79.13.8217-8229.2005]

24 **Voisset C**, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. *J Gen Virol* 2006; **87**: 2577-2581 [PMID: 16894196 DOI: 10.1099/vir.0.81932-0]

25 **Lavillette D**, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. *J Virol* 2005; **79**: 6023-6034 [PMID: 15857988 DOI: 10.1128/JVI.79.10.6023-6034.2005]

26 **Barth H**, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. *J Biol Chem* 2003; **278**: 41003-41012 [PMID: 12867431 DOI: 10.1074/jbc.M302267200]

27 **Agnello V**, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci USA* 1999; **96**: 12766-12771 [PMID: 10535997 DOI: 10.1073/pnas.96.22.12766]

28 **Pileri P**, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S. Binding of hepatitis C virus to CD81. *Science* 1998; **282**: 938-941 [PMID: 9794763 DOI: 10.1126/science.282.5390.938]

29 **Scarselli E**, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. *EMBO J* 2002; **21**: 5017-5025 [PMID: 12356718 DOI: 10.1093/emboj/cdf529]

30 **Evans MJ**, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wölk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature* 2007; **446**: 801-805 [PMID: 17325668 DOI: 10.1038/nature05654]

31 **Ploss A**, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. *Nature* 2009; **457**: 882-886 [PMID: 19182773 DOI: 10.1038/nature07684]

32 **Griffin BA**. Lipid metabolism. *Surgery* (Oxford) 2013; **31**: 267-272 [DOI: 10.1016/j.mpsur.2013.04.006]

33 **Chappell DA**, Medh JD. Receptor-mediated mechanisms of lipoprotein remnant catabolism. *Prog Lipid Res* 1998; **37**: 393-422 [PMID: 10209655]

34 **Mead JR**, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. *J Mol Med* (Berl) 2002; **80**: 753-769 [PMID: 12483461 DOI: 10.1007/s00109-002-0384-9]

35 **Rosenson RS**, Brewer HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. *Circulation* 2012; **125**: 1905-1919 [PMID: 22508840 DOI: 10.1161/CIRCULATIONAHA.111.066589]

36 **Brown WV**. High-density lipoprotein and transport of cholesterol and triglyceride in blood. *J Clin Lipidol* 2007; **1**: 7-19 [PMID: 21291664 DOI: 10.1016/j.jacl.2007.02.001]

37 **Serfaty L**, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. *J Hepatol* 2001; **34**: 428-434 [PMID: 11322205]

38 **Siagris D**, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. *J Viral Hepat* 2006; **13**: 56-61 [PMID: 16364083 DOI: 10.1111/j.1365-2893.2005.00655.x]

39 **Poynard T**, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 2003; **38**: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267]

40 **Walters KA**, Joyce MA, Thompson JC, Smith MW, Yeh MM, Proll S, Zhu LF, Gao TJ, Kneteman NM, Tyrrell DL, Katze MG. Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response. *PLoS Pathog* 2006; **2**: e59 [PMID: 16789836 DOI: 10.1371/journal.ppat.0020059]

41 **Su AI**, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV. Genomic analysis of the host response to hepatitis C virus infection. *Proc Natl Acad Sci USA* 2002; **99**: 15669-15674 [PMID: 12441396 DOI: 10.1073/pnas.202608199]

42 **Gopal K**, Johnson TC, Gopal S, Walfish A, Bang CT, Suwandhi P, Pena-Sahdala HN, Clain DJ, Bodenheimer HC, Min AD. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. *Hepatology* 2006; **44**: 335-340 [PMID: 16871569 DOI: 10.1002/hep.21261]

43 **Ikeda M**, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. *Hepatology* 2006; **44**: 117-125 [PMID: 16799963 DOI: 10.1002/hep.21232]

44 **Delang L**, Paeshuyse J, Vliegen I, Leyssen P, Obeid S, Durantel D, Zoulim F, Op de Beeck A, Neyts J. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. *Hepatology* 2009; **50**: 6-16 [PMID: 19437494 DOI: 10.1002/hep.22916]

45 **Milazzo L**, Meroni L, Galazzi M, Cesari M, Caramma I, Marchetti G, Galli M, Antinori S. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. *J Viral Hepat* 2009; **16**: 479-484 [PMID: 19215577 DOI: 10.1111/j.1365-2893.2009.01104.x]

46 **O'Leary JG**, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. *Hepatology* 2007; **45**: 895-898 [PMID: 17393518 DOI: 10.1002/hep.21554]

47 **Bader T**, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, Seres K, Hasan M. Fluvastatin inhibits hepatitis C replication in humans. *Am J Gastroenterol* 2008; **103**: 1383-1389 [PMID: 18410471 DOI: 10.1111/j.1572-0241.2008.01876.x]

48 **Forde KA**, Law C, O'Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? *World J Gastroenterol* 2009; **15**: 5020-5027 [PMID: 19859994]

49 **Milazzo L**, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. *J Antimicrob Chemother* 2010; **65**: 735-740 [PMID: 20118492 DOI: 10.1093/jac/dkq002]

50 **Atsukawa M**, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. *J Gastroenterol Hepatol* 2013; **28**: 51-56 [PMID: 22989264 DOI: 10.1111/j.1440-1746.2012.07267.x]

51 **Harrison SA**, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. *Hepatology* 2010; **52**: 864-874 [PMID: 20568303 DOI: 10.1002/hep.23787]

52 **Rao GA**, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. *Gastroenterology* 2011; **140**: 144-152 [PMID: 20833169 DOI: 10.1053/j.gastro.2010.08.055]

53 **Fujita N**, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, Konishi M, Iwasa M, Watanabe S, Adachi Y. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. *J Viral Hepat* 2006; **13**: 441-448 [PMID: 16792537 DOI: 10.1111/j.1365-2893.2005.00718.x]

54 **Dai CY**, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. *J Hepatol* 2008; **49**: 9-16 [PMID: 18486265 DOI: 10.1016/j.jhep.2008.03.016]

55 **Marzouk D**, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, Chaturvedi N, Mohamed MK, Fontanet A. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. *Gut* 2007; **56**: 1105-1110 [PMID: 16956918 DOI: 10.1136/gut.2006.091983]

56 **Romero-Gómez M**. Insulin resistance and hepatitis C. *World J Gastroenterol* 2006; **12**: 7075-7080 [PMID: 17131467]

57 **Romero-Gómez M**, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. *Hepatology* 2009; **50**: 1702-1708 [PMID: 19845037 DOI: 10.1002/hep.23206]

58 **Khattab M**, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. *Liver Int* 2010; **30**: 447-454 [PMID: 19919569 DOI: 10.1111/j.1478-3231.2009.02171.x]

59 **Bartenschlager R**, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. *Trends Microbiol* 2011; **19**: 95-103 [PMID: 21146993 DOI: 10.1016/j.tim.2010.11.005]

60 **André P**, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Bréchot C, Paranhos-Baccalà G, Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. *J Virol* 2002; **76**: 6919-6928 [PMID: 12072493]

61 **Nielsen SU**, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. *J virol* 2006; **80**: 2418-2428 [DOI: 10.1128/Jvi.80.5.2418-2428.2006]

62 **Diaz O**, Delers F, Maynard M, Demignot S, Zoulim F, Chambaz J, Trépo C, Lotteau V, André P. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. *J Gen Virol* 2006; **87**: 2983-2991 [PMID: 16963757 DOI: 10.1099/vir.0.82033-0]

63 **Rhainds D**, Brissette L. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. *Int J Biochem Cell Biol* 2004; **36**: 39-77 [PMID: 14592533]

64 **Rigotti A**, Miettinen HE, Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. *Endocr Rev* 2003; **24**: 357-387 [PMID: 12788804]

65 **Röhrl C**, Stangl H. HDL endocytosis and resecretion. *Biochim Biophys Acta* 2013; **1831**: 1626-1633 [PMID: 23939397 DOI: 10.1016/j.bbalip.2013.07.014]

66 **Dao Thi VL**, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M. Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. *J Biol Chem* 2012; **287**: 31242-31257 [PMID: 22767607 DOI: 10.1074/jbc.M112.365924]

67 **Maillard P**, Huby T, Andréo U, Moreau M, Chapman J, Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. *FASEB J* 2006; **20**: 735-737 [PMID: 16476701 DOI: 10.1096/fj.05-4728fje]

68 **Zeisel MB**, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. *Hepatology* 2007; **46**: 1722-1731 [PMID: 18000990 DOI: 10.1002/hep.21994]

69 **Catanese MT**, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. *J Virol* 2007; **81**: 8063-8071 [PMID: 17507483 DOI: 10.1128/JVI.00193-07]

70 **Meuleman P**, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. *Hepatology* 2012; **55**: 364-372 [PMID: 21953761 DOI: 10.1002/hep.24692]

71 **Nieland TJ**, Penman M, Dori L, Krieger M, Kirchhausen T. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. *Proc Natl Acad Sci USA* 2002; **99**: 15422-15427 [PMID: 12438696 DOI: 10.1073/pnas.222421399]

72 **Voisset C**, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. *J Biol Chem* 2005; **280**: 7793-7799 [PMID: 15632171 DOI: 10.1074/jbc.M411600200]

73 **Dreux M**, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. *J Biol Chem* 2006; **281**: 18285-18295 [PMID: 16675450 DOI: 10.1074/jbc.M602706200]

74 **Brimacombe CL**, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. *J Virol* 2011; **85**: 596-605 [PMID: 20962076 DOI: 10.1128/JVI.01592-10]

75 **Mittapalli GK**, Jackson A, Zhao F, Lee H, Chow S, McKelvy J, Wong-Staal F, Macdonald JE. Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. *Bioorg Med Chem Lett* 2011; **21**: 6852-6855 [PMID: 21978675 DOI: 10.1016/j.bmcl.2011.09.019]

76 **Syder AJ**, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. *J Hepatol* 2011; **54**: 48-55 [PMID: 20932595 DOI: 10.1016/j.jhep.2010.06.024]

77 **Zahid MN**, Turek M, Xiao F, Thi VL, Guérin M, Fofana I, Bachellier P, Thompson J, Delang L, Neyts J, Bankwitz D, Pietschmann T, Dreux M, Cosset FL, Grunert F, Baumert TF, Zeisel MB. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. *Hepatology* 2013; **57**: 492-504 [PMID: 23081796 DOI: 10.1002/hep.26097]

78 **Catanese MT**, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. *J Virol* 2010; **84**: 34-43 [PMID: 19828610 DOI: 10.1128/JVI.02199-08]

79 **Guo L**, Chen M, Song Z, Daugherty A, Li XA. C323 of SR-BI is required for SR-BI-mediated HDL binding and cholesteryl ester uptake. *J Lipid Res* 2011; **52**: 2272-2278 [PMID: 21917726 DOI: 10.1194/jlr.M019091]

80 **Goldstein JL**, Brown MS. The LDL receptor. *Arterioscler Thromb Vasc Biol* 2009; **29**: 431-438 [PMID: 19299327 DOI: 10.1161/ATVBAHA.108.179564]

81 **Wünschmann S**, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. *J Virol* 2000; **74**: 10055-10062 [PMID: 11024134]

82 **Monazahian M**, Böhme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. *J Med Virol* 1999; **57**: 223-229 [PMID: 10022791]

83 **Molina S**, Castet V, Fournier-Wirth C, Pichard-Garcia L, Avner R, Harats D, Roitelman J, Barbaras R, Graber P, Ghersa P, Smolarsky M, Funaro A, Malavasi F, Larrey D, Coste J, Fabre JM, Sa-Cunha A, Maurel P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. *J Hepatol* 2007; **46**: 411-419 [PMID: 17156886 DOI: 10.1016/j.jhep.2006.09.024]

84 Owen DM, Huang H, Ye J, Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394(1): 99-108 [PMID: ISI: 000271438000013 DOI: 10.1016/j.virol.2009.08.037]

85 **Mazumdar B**, Banerjee A, Meyer K, Ray R. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. *Hepatology* 2011; **54**: 1149-1156 [PMID: 21735466 DOI: 10.1002/hep.24523]

86 **Hishiki T**, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K. Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. *J Virol* 2010; **84**: 12048-12057 [PMID: 20826689 DOI: 10.1128/JVI.01063-10]

87 **Prentoe J**, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus. *J Virol* 2014; **88**: 1725-1739 [PMID: 24257605 DOI: 10.1128/JVI.02017-13]

88 **Albecka A**, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Tercé F, Duverlie G, Rouillé Y, Dubuisson J. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. *Hepatology* 2012; **55**: 998-1007 [PMID: 22121002 DOI: 10.1002/hep.25501]

89 **Sainz B**, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. *Nat Med* 2012; **18**: 281-285 [PMID: 22231557 DOI: 10.1038/nm.2581]

90 **Yu L**. The structure and function of Niemann-Pick C1-like 1 protein. *Curr Opin Lipidol* 2008; **19**: 263-269 [PMID: 18460917 DOI: 10.1097/MOL.0b013e3282f9b563]

91 **Altmann SW**, Davis HR, Zhu LJ, Yao XR, Hoos LM, Tetzloff G, Iyer SPN, Maguire M, Golovko A, Zeng M, Wang LQ, Murgolo N, Graziano MP. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. *Science* 2004; **303**: 1201-1204 [PMID: 14976318]

92 **Temel RE**, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA, Davies JP, Nilsson LM, Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. *J Clin Invest* 2007; **117**: 1968-1978 [PMID: 17571164 DOI: 10.1172/JCI30060]

93 **Bays HE**, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. *Expert Rev Cardiovasc Ther* 2008; **6**: 447-470 [PMID: 18402536 DOI: 10.1586/14779072.6.4.447]

94 **Germi R**, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. *J Med Virol* 2002; **68**: 206-215 [PMID: 12210409 DOI: 10.1002/jmv.10196]

95 **Barth H**, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. *J Virol* 2006; **80**: 10579-10590 [PMID: 16928753 DOI: 10.1128/JVI.00941-06]

96 **Koutsoudakis G**, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. *J Virol* 2006; **80**: 5308-5320 [PMID: 16699011 DOI: 10.1128/JVI.02460-05]

97 **Jiang J**, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. *J Virol* 2012; **86**: 7256-7267 [PMID: 22532692 DOI: 10.1128/JVI.07222-11]

98 **Shi Q**, Jiang J, Luo G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. *J Virol* 2013; **87**: 6866-6875 [PMID: 23576506 DOI: 10.1128/JVI.03475-12]

99 **Heeren J**, Niemeier A, Merkel M, Beisiegel U. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. *J Mol Med* (Berl) 2002; **80**: 576-584 [PMID: 12226739 DOI: 10.1007/s00109-002-0351-5]

100 **Zheng C**, Murdoch SJ, Brunzell JD, Sacks FM. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. *Arterioscler Thromb Vasc Biol* 2006; **26**: 891-896 [PMID: 16410459 DOI: 10.1161/01.ATV.0000203512.01007.3d]

101 **Andréo U**, Maillard P, Kalinina O, Walic M, Meurs E, Martinot M, Marcellin P, Budkowska A. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. *Cell Microbiol* 2007; **9**: 2445-2456 [PMID: 17517063 DOI: 10.1111/j.1462-5822.2007.00972.x]

102 **Maillard P**, Walic M, Meuleman P, Roohvand F, Huby T, Le Goff W, Leroux-Roels G, Pécheur EI, Budkowska A. Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. *PLoS One* 2011; **6**: e26637 [PMID: 22039521 DOI: 10.1371/journal.pone.0026637]

103 **Shimizu Y**, Hishiki T, Sugiyama K, Ogawa K, Funami K, Kato A, Ohsaki Y, Fujimoto T, Takaku H, Shimotohno K. Lipoprotein lipase and hepatic triglyceride lipase reduce the infectivity of hepatitis C virus (HCV) through their catalytic activities on HCV-associated lipoproteins. *Virology* 2010; **407**: 152-159 [PMID: 20822787 DOI: 10.1016/j.virol.2010.08.011]

104 **von Hahn T**, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. *Hepatology* 2006; **43**: 932-942 [PMID: 16628670 DOI: 10.1002/Hep.21139]

105 **Westhaus S**, Bankwitz D, Ernst S, Rohrmann K, Wappler I, Agné C, Luchtefeld M, Schieffer B, Sarrazin C, Manns MP, Pietschmann T, Ciesek S, von Hahn T. Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein. *Hepatology* 2013; **57**: 1716-1724 [PMID: 23212706 DOI: 10.1002/hep.26190]

106 1 **Lavie M**, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, Dubuisson J. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. *Hepatology* 2006; **44**: 1626-1634 [PMID: 17133472 DOI: 10.1002/Hep.21406]

107 **Cai Z**, Cai L, Jiang J, Chang KS, van der Westhuyzen DR, Luo G. Human serum amyloid A protein inhibits hepatitis C virus entry into cells. *J Virol* 2007; **81**: 6128-6133 [PMID: 17329325 DOI: 10.1128/JVI.02627-06]

108 **Meunier JC**, Engle RE, Faulk K, Zhao M, Bartosch B, Alter H, Emerson SU, Cosset FL, Purcell RH, Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. *Proc Natl Acad Sci USA* 2005; **102**: 4560-4565 [PMID: 15767578 DOI: 10.1073/pnas.0501275102]

109 **Dreux M**, Dao Thi VL, Fresquet J, Guérin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. *PLoS Pathog* 2009; **5**: e1000310 [PMID: 19229312 DOI: 10.1371/journal.ppat.1000310]

110 **Vercauteren K**, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. *Hepatology* 2014; Epub ahead of print [PMID: 24797654 DOI: 10.1002/hep.27196]

111 **Kapadia SB**, Barth H, Baumert T, McKeating JA, Chisari FV. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. *J Virol* 2007; **81**: 374-383 [PMID: 17050612 DOI: 10.1128/JVI.01134-06]

112 **Dreux M**, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, Pécheur EI, Cosset FL. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. *J Biol Chem* 2007; **282**: 32357-32369 [PMID: 17761674 DOI: 10.1074/jbc.M705358200]

113 **Bankwitz D**, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Foung SK, Pécheur EI, Pietschmann T. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. *J Virol* 2010; **84**: 5751-5763 [PMID: 20357091 DOI: 10.1128/JVI.02200-09]

114 **Brazzoli M**, Bianchi A, Filippini S, Weiner A, Zhu Q, Pizza M, Crotta S. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. *J Virol* 2008; **82**: 8316-8329 [PMID: 18579606 DOI: 10.1128/JVI.00665-08]

115 **Krieger SE**, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. *Hepatology* 2010; **51**: 1144-1157 [PMID: 20069648 DOI: 10.1002/hep.23445]

116 **Harris HJ**, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, Jennings A, Hu K, Yuan F, Deng H, Hubscher SG, Han JH, Balfe P, McKeating JA. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. *J Virol* 2008; **82**: 5007-5020 [PMID: 18337570 DOI: 10.1128/JVI.02286-07]

117 **Rhainds D**, Bourgeois P, Bourret G, Huard K, Falstrault L, Brissette L. Localization and regulation of SR-BI in membrane rafts of HepG2 cells. *J Cell Sci* 2004; **117**: 3095-3105 [PMID: 15226391 DOI: 10.1242/jcs.01182]

118 **Charrin S**, Manié S, Thiele C, Billard M, Gerlier D, Boucheix C, Rubinstein E. A physical and functional link between cholesterol and tetraspanins. *Eur J Immunol* 2003; **33**: 2479-2489 [PMID: 12938224 DOI: 10.1002/eji.200323884]

119 **Cherukuri A**, Shoham T, Sohn HW, Levy S, Brooks S, Carter R, Pierce SK. The tetraspanin CD81 is necessary for partitioning of coligated CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. *J Immunol* 2004; **172**: 370-380 [PMID: 14688345]

120 **Harris HJ**, Davis C, Mullins JG, Hu K, Goodall M, Farquhar MJ, Mee CJ, McCaffrey K, Young S, Drummer H, Balfe P, McKeating JA. Claudin association with CD81 defines hepatitis C virus entry. *J Biol Chem* 2010; **285**: 21092-21102 [PMID: 20375010 DOI: 10.1074/jbc.M110.104836]

121 **Bertaux C**, Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. *J Virol* 2006; **80**: 4940-4948 [PMID: 16641285 DOI: 10.1128/JVI.80.10.4940-4948.2006]

122 **Voisset C**, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. *Cell Microbiol* 2008; **10**: 606-617 [PMID: 17979982 DOI: 10.1111/j.1462-5822.2007.01070.x]

123 **Schwarz AK**, Grove J, Hu K, Mee CJ, Balfe P, McKeating JA. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. *J Virol* 2009; **83**: 12407-12414 [PMID: 19776133 DOI: 10.1128/JVI.01552-09]

124 **Grove J**, Huby T, Stamataki Z, Vanwolleghem T, Meuleman P, Farquhar M, Schwarz A, Moreau M, Owen JS, Leroux-Roels G, Balfe P, McKeating JA. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. *J Virol* 2007; **81**: 3162-3169 [PMID: 17215280 DOI: 10.1128/JVI.02356-06]

125 **Pichler H**, Riezman H. Where sterols are required for endocytosis. *Biochim Biophys Acta* 2004; **1666**: 51-61 [PMID: 15519308 DOI: 10.1016/j.bbamem.2004.05.011]

126 **Blanchard E**, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, Rouillé Y. Hepatitis C virus entry depends on clathrin-mediated endocytosis. *J Virol* 2006; **80**: 6964-6972 [PMID: 16809302 DOI: 10.1128/JVI.00024-06]

127 **Lavillette D**, Pécheur EI, Donot P, Fresquet J, Molle J, Corbau R, Dreux M, Penin F, Cosset FL. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. *J Virol* 2007; **81**: 8752-8765 [PMID: 17537855 DOI: 10.1128/JVI.02642-06]

128 **Lavillette D**, Bartosch B, Nourrisson D, Verney G, Cosset FL, Penin F, Pécheur EI. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. *J Biol Chem* 2006; **281**: 3909-3917 [PMID: 16356932 DOI: 10.1074/jbc.M509747200]

129 **Haid S**, Pietschmann T, Pécheur EI. Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. *J Biol Chem* 2009; **284**: 17657-17667 [PMID: 19411248 DOI: 10.1074/jbc.M109.014647]

130 **Moradpour D**, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol* 2007; **5**: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]

131 **Diamond DL**, Syder AJ, Jacobs JM, Sorensen CM, Walters KA, Proll SC, McDermott JE, Gritsenko MA, Zhang Q, Zhao R, Metz TO, Camp DG, Waters KM, Smith RD, Rice CM, Katze MG. Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. *PLoS Pathog* 2010; **6**: e1000719 [PMID: 20062526 DOI: 10.1371/journal.ppat.1000719]

132 **Li Z**, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. *Cell Metab* 2006; **3**: 321-331 [PMID: 16679290 DOI: 10.1016/j.cmet.2006.03.007]

133 **Sakamoto H**, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, Tsukuda T, Shimma N, Aoki Y, Arisawa M, Kohara M, Sudoh M. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. *Nat Chem Biol* 2005; **1**: 333-337 [PMID: 16408072 DOI: 10.1038/nchembio742]

134 **Berger KL**, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. *Proc Natl Acad Sci USA* 2009; **106**: 7577-7582 [PMID: 19376974 DOI: 10.1073/pnas.0902693106]

135 **Romero-Brey I**, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, Santarella-Mellwig R, Habermann A, Hoppe S, Kallis S, Walther P, Antony C, Krijnse-Locker J, Bartenschlager R. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. *PLoS Pathog* 2012; **8**: e1003056 [PMID: 23236278 DOI: 10.1371/journal.ppat.1003056]

136 **Martin S**, Parton RG. Lipid droplets: a unified view of a dynamic organelle. *Nat Rev Mol Cell Biol* 2006; **7**: 373-378 [PMID: 16550215 DOI: 10.1038/nrm1912]

137 **Moradpour D**, Englert C, Wakita T, Wands JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. *Virology* 1996; **222**: 51-63 [PMID: 8806487 DOI: 10.1006/viro.1996.0397]

138 **Rouillé Y**, Helle F, Delgrange D, Roingeard P, Voisset C, Blanchard E, Belouzard S, McKeating J, Patel AH, Maertens G, Wakita T, Wychowski C, Dubuisson J. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. *J Virol* 2006; **80**: 2832-2841 [PMID: 16501092 DOI: 10.1128/JVI.80.6.2832-2841.2006]

139 **Miyanari Y**, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K. The lipid droplet is an important organelle for hepatitis C virus production. *Nat Cell Biol* 2007; **9**: 1089-1097 [PMID: 17721513 DOI: 10.1038/ncb1631]

140 **Moriya K**, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J Gen Virol* 1997; **78** (Pt 7): 1527-1531 [PMID: 9225025]

141 **Olofsson SO**, Boström P, Andersson L, Rutberg M, Perman J, Borén J. Lipid droplets as dynamic organelles connecting storage and efflux of lipids. *Biochim Biophys Acta* 2009; **1791**: 448-458 [PMID: 18775796 DOI: 10.1016/j.bbalip.2008.08.001]

142 **Huang H**, Sun F, Owen DM, Li W, Chen Y, Gale M, Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. *Proc Natl Acad Sci USA* 2007; **104**: 5848-5853 [PMID: 17376867 DOI: 10.1073/pnas.0700760104]

143 **Thomssen R**, Bonk S, Propfe C, Heermann KH, Köchel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. *Med Microbiol Immunol* 1992; **181**: 293-300 [PMID: 1335546]

144 **Gastaminza P**, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. *J Virol* 2008; **82**: 2120-2129 [PMID: 18077707 DOI: 10.1128/JVI.02053-07]

145 **Nahmias Y**, Goldwasser J, Casali M, van Poll D, Wakita T, Chung RT, Yarmush ML. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. *Hepatology* 2008; **47**: 1437-1445 [PMID: 18393287 DOI: 10.1002/hep.22197]

146 **Gastaminza P**, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. *J Virol* 2006; **80**: 11074-11081 [PMID: 16956946 DOI: 10.1128/JVI.01150-06]

147 **Tao W**, Xu C, Ding Q, Li R, Xiang Y, Chung J, Zhong J. A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles. *Virology* 2009; **395**: 67-76 [PMID: 19793603 DOI: 10.1016/j.virol.2009.09.006]

148 **Icard V**, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, Penin F, Lotteau V, André P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. *PLoS One* 2009; **4**: e4233 [PMID: 19156195 DOI: 10.1371/journal.pone.0004233]

149 **Nourbakhsh M**, Douglas DN, Pu CH, Lewis JT, Kawahara T, Lisboa LF, Wei E, Asthana S, Quiroga AD, Law LM, Chen C, Addison WR, Nelson R, Houghton M, Lehner R, Kneteman NM. Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. *J Hepatol* 2013; **59**: 336-343 [PMID: 23542347 DOI: 10.1016/j.jhep.2013.03.022]

150 **Fazio S**, Linton MF, Swift LL. The cell biology and physiologic relevance of ApoE recycling. *Trends Cardiovasc Med* 2000; **10**: 23-30 [PMID: 11150725]

151 **Chang KS**, Jiang J, Cai Z, Luo G. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. *J Virol* 2007; **81**: 13783-13793 [PMID: 17913825 DOI: 10.1128/JVI.01091-07]

152 **Jiang J**, Luo G. Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. *J Virol* 2009; **83**: 12680-12691 [PMID: 19793818 DOI: 10.1128/JVI.01476-09]

153 **Long G**, Hiet MS, Windisch MP, Lee JY, Lohmann V, Bartenschlager R. Mouse hepatic cells support assembly of infectious hepatitis C virus particles. *Gastroenterology* 2011; **141**: 1057-1066 [PMID: 21699799 DOI: 10.1053/j.gastro.2011.06.010]

154 **Hueging K**, Doepke M, Vieyres G, Bankwitz D, Frentzen A, Doerrbecker J, Gumz F, Haid S, Wölk B, Kaderali L, Pietschmann T. Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly. *J Virol* 2014; **88**: 1433-1446 [PMID: 24173232 DOI: 10.1128/JVI.01815-13]

155 **Benga WJ**, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, Luo G, McLauchlan J, Baumert TF, Schuster C. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. *Hepatology* 2010; **51**: 43-53 [PMID: 20014138 DOI: 10.1002/hep.23278]

156 **Merz A**, Long G, Hiet MS, Brügger B, Chlanda P, Andre P, Wieland F, Krijnse-Locker J, Bartenschlager R. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. *J Biol Chem* 2011; **286**: 3018-3032 [PMID: 21056986 DOI: 10.1074/jbc.M110.175018]

157 **Meunier JC**, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU. Apolipoprotein c1 association with hepatitis C virus. *J Virol* 2008; **82**: 9647-9656 [PMID: 18667498 DOI: 10.1128/JVI.00914-08]

158 **Aizaki H**, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MM, Miyamura T, Wakita T, Suzuki T. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. *J Virol* 2008; **82**: 5715-5724 [PMID: 18367533 DOI: 10.1128/JVI.02530-07]

159 **Yamamoto M**, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, Wakita T, Suzuki T. Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus. *J Gen Virol* 2011; **92**: 2082-2087 [PMID: 21593275 DOI: 10.1099/vir.0.032391-0]

160 **Grove J**, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. *J Virol* 2008; **82**: 12020-12029 [PMID: 18829747 DOI: 10.1128/JVI.01569-08]

161 **Prentoe J**, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. *J Virol* 2011; **85**: 2224-2234 [PMID: 21123377 DOI: 10.1128/JVI.01594-10]

162 **Koutsoudakis G**, Dragun J, Pérez-Del-Pulgar S, Coto-Llerena M, Mensa L, Crespo G, González P, Navasa M, Forns X. Interplay between basic residues of hepatitis C virus glycoprotein E2 with viral receptors, neutralizing antibodies and lipoproteins. *PLoS One* 2012; **7**: e52651 [PMID: 23300734 DOI: 10.1371/journal.pone.0052651]

163 **Thomssen R**, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. *Med Microbiol Immunol* 1993; **182**: 329-334 [PMID: 8121333]

164 **Felmlee DJ**, Fauvelle C, Heydmann L, Hiet MS, Fofana I, Bartenschlager R, Stoll-Keller F, Zeisel MB, Fafi-Kremer S, Baumert TF. Hepatitis C Virus Liver Transplantation Escape Variant Is Characterized by Both Enhanced Triglyceride-Rich Lipoprotein Association and Sensitivity to Apoe Antibodies. *J Hepatol* 2013; **58**: S468-S468

165 **Fafi-Kremer S**, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. *J Exp Med* 2010; **207**: 2019-2031 [PMID: 20713596 DOI: 10.1084/jem.20090766]

166 **Molina S**, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. *J Virol* 2008; **82**: 569-574 [PMID: 17942559 DOI: 10.1128/JVI.01443-07]

167 **Tan YJ**, Lim SP, Ng P, Goh PY, Lim SG, Tan YH, Hong W. CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. *Virology* 2003; **308**: 250-269 [PMID: 12706076]

168 **Meuleman P**, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. *Hepatology* 2008; **48**: 1761-1768 [PMID: 19030166 DOI: 10.1002/hep.22547]

169 **Lacek K**, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Słowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. *J Hepatol* 2012; **57**: 17-23 [PMID: 22414763 DOI: 10.1016/j.jhep.2012.02.018]

**P-Reviewer:** Shimizu Y **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**



**Figure 1 schematic representation of lipoprotein metabolism.** Refer to text for further details. CM: Chylomicron; CMR: Chylomicron remnant Apo, apolipoprotein; VLDL: Very low density lipoprotein; IDL: Intermediate density lipoprotein; LDL: Low density lipoprotein; HL: Hepatic lipase; LPL: Lipoprotein lipase; SR-BI: Scavenger receptor class B type I; LDL-R: Low density lipoprotein receptor; LRP1: Low density lipoprotein receptor-related protein 1.